NeuroTheranostics

NeuroTheranostics, Inc. (NTI) is a privately held preclinical development-stage neuroscience company that was formed in February 2015 to develop novel therapies and diagnostics for traumatic brain injury (TBI) and TBI-associated neurodegenerative disorders. NTI will make a significant impact on the TBI therapeutics and chronic TBI diagnostics market with an intranasal or intravenous-infusion therapy to be administered starting from the acute to subacute stages of TBI, i.e., within hours to days following the initial traumatic event. The R&D outfit of the company is located in a business and technology park (TechTown) in Detroit, Michigan. Our management and scientific/clinical advisory teams bring together the complementary expertise of business and finance experts with decades of experience in multiple technology startups, large scale turnarounds, and large financial exits and post-merger restructurings, neuroscientists with TBI drug and diagnostic development expertise, neurosurgeons, and emergency and critical care doctors with interest and clinical experience in TBI drug development and treatment.